| scholarly article | Q13442814 |
| P2093 | author name string | Mark Appleby | |
| Mary E Brunkow | |||
| Karen Staehling-Hampton | |||
| James C Geoghegan | |||
| Changpu Yu | |||
| David G Winkler | |||
| John A Latham | |||
| May Kung Sutherland | |||
| John E Skonier | |||
| Diana Shpektor | |||
| Brian R Kovacevich | |||
| Mechtild Jonas | |||
| Trenton Hayes | |||
| P2860 | cites work | The BMP antagonist Gremlin regulates outgrowth, chondrogenesis and programmed cell death in the developing limb | Q22010774 |
| Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin | Q22253980 | ||
| Crystal structure of the BMP-2-BRIA ectodomain complex | Q22254423 | ||
| Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST) | Q24290838 | ||
| The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4 | Q24315313 | ||
| Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein | Q24536172 | ||
| A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait | Q24561917 | ||
| Crystal structure of the human TbetaR2 ectodomain--TGF-beta3 complex | Q27637864 | ||
| Mutant Glu781-->Ala of the rat kidney Na+,K(+)-ATPase displays low cation affinity and catalyzes ATP hydrolysis at a high rate in the absence of potassium ions. | Q54182264 | ||
| Ion motive ATPases. I. Ubiquity, properties, and significance to cell function | Q61889649 | ||
| Interaction of fluorescein isothiocyanate with the (H+ + K+)-ATPase | Q67292304 | ||
| Phosphorylation of H+/K+-ATPase by inorganic phosphate. The role of K+ and SCH 28080 | Q67913708 | ||
| A monoclonal antibody against pig gastric H+/K(+)-ATPase, which binds to the cytosolic E1.K+ form | Q68452740 | ||
| Demonstration of the electrogenicity of proton translocation during the phosphorylation step in gastric H+K(+)-ATPase | Q68455513 | ||
| Eosin, a fluorescent marker for the high-affinity ATP site of (K+ + H+)-ATPase | Q68965451 | ||
| Conformational states of (K+ + H+)-ATPase studied using tryptic digestion as a tool | Q69813541 | ||
| Cranial CT findings in sclerosteosis | Q70139328 | ||
| Two residues that may ligate Ca2+ in transmembrane domain six of the plasma membrane Ca(2+)-ATPase | Q71585663 | ||
| Determination of total protein | Q71746469 | ||
| Scanning mutagenesis reveals a similar pattern of mutation sensitivity in transmembrane sequences M4, M5, and M6, but not in M8, of the Ca2+-ATPase of sarcoplasmic reticulum (SERCA1a) | Q71825675 | ||
| Sodium acts as a potassium analog on gastric H,K-ATPase | Q72149275 | ||
| Tertiary amines as antagonists of both the luminal and cytosolic K(+)-site of gastric H,K-ATPase | Q72734762 | ||
| Kinetics of transient pump currents generated by the (H,K)-ATPase after an ATP concentration jump | Q72971337 | ||
| Identification of Asp804 and Asp808 as Na+ and K+ coordinating residues in alpha-subunit of renal Na,K-ATPase | Q72991874 | ||
| Functional consequences of mutations in the transmembrane core region for cation translocation and energy transduction in the Na+,K(+)-ATPase and the SR Ca(2+)-ATPase | Q73956929 | ||
| Structural basis of BMP signalling inhibition by the cystine knot protein Noggin | Q27640149 | ||
| Multilineage potential of adult human mesenchymal stem cells | Q27860737 | ||
| Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg's disease | Q28182705 | ||
| LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development | Q28206790 | ||
| Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms | Q28210549 | ||
| Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells | Q28261235 | ||
| Structural organization, ion transport, and energy transduction of P-type ATPases | Q28279229 | ||
| Sclerosteosis. | Q33592556 | ||
| Bone morphogenetic proteins induce gremlin, a protein that limits their activity in osteoblasts | Q33927389 | ||
| Molecular events caused by mechanical stress in bone | Q33936567 | ||
| Do bone cells behave like a neuronal network? | Q34768029 | ||
| The clinical features of sclerosteosis. A review of the manifestations in twenty-five affected individuals | Q35068528 | ||
| Developmental regulation of myosin gene expression in mouse cardiac muscle | Q36224282 | ||
| Role of negatively charged residues in the fifth and sixth transmembrane domains of the catalytic subunit of gastric H+,K+-ATPase | Q36835003 | ||
| Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts | Q37388231 | ||
| A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities | Q37444686 | ||
| Role of water in the energy of hydrolysis of phosphate compounds--energy transduction in biological membranes. | Q38265110 | ||
| Inhibin suppresses and activin stimulates osteoblastogenesis and osteoclastogenesis in murine bone marrow cultures | Q38293716 | ||
| The mouse osteocalcin gene cluster contains three genes with two separate spatial and temporal patterns of expression. | Q38312132 | ||
| Location of high affinity Ca2+-binding sites within the predicted transmembrane domain of the sarcoplasmic reticulum Ca2+-ATPase | Q38344356 | ||
| Functional expression of gastric H+,K(+)-ATPase and site-directed mutagenesis of the putative cation binding site and catalytic center | Q38361888 | ||
| Roles of bone morphogenetic protein type I receptors and Smad proteins in osteoblast and chondroblast differentiation. | Q38614636 | ||
| Occlusion of K ions in the unphosphorylated sodium pump | Q40240463 | ||
| Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity | Q40654190 | ||
| Differentiation of murine preosteoblastic KS483 cells depends on autocrine bone morphogenetic protein signaling during all phases of osteoblast formation | Q40676893 | ||
| Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A. | Q40744204 | ||
| Extracellular matrix-associated bone morphogenetic proteins are essential for differentiation of murine osteoblastic cells in vitro | Q40958301 | ||
| Mutational Analysis of Putative SCH 28080 Binding Sites of the Gastric H+,K+-ATPase | Q41099747 | ||
| Asp804 and Asp808 in the transmembrane domain of the Na,K-ATPase alpha subunit are cation coordinating residues | Q41150449 | ||
| Ethanol stimulates expression of functional H+,K(+)-ATPase in SF9 cells | Q41343874 | ||
| The negative charge of glutamic acid-820 in the gastric H+,K+-ATPase alpha-subunit is essential for K+ activation of the enzyme activity | Q41829313 | ||
| Functional expression of gastric H,K-ATPase using the baculovirus expression system | Q42069681 | ||
| Determination of the epitope for the inhibitory monoclonal antibody 5-B6 on the catalytic subunit of gastric Mg2+-dependent H+-transporting and K+-stimulated ATPase | Q42078291 | ||
| Human bone marrow osteoprogenitors express estrogen receptor-alpha and bone morphogenetic proteins 2 and 4 mRNA during osteoblastic differentiation | Q42479235 | ||
| Site-directed mutagenesis of virtually any plasmid by eliminating a unique site | Q42611278 | ||
| Bone biomechanical properties in prostaglandin EP1 and EP2 knockout mice | Q43705372 | ||
| Amino-acid sequence of a Ca2+ + Mg2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from its complementary DNA sequence | Q48376136 | ||
| Amino-acid sequence of the catalytic subunit of the (Na+ + K+)ATPase deduced from a complementary DNA. | Q48376146 | ||
| Sclerosteosis: neurogenetic and pathophysiologic analysis of an American kinship. | Q50593171 | ||
| Bone morphogenetic protein signals are required for cartilage formation and differently regulate joint development during skeletogenesis. | Q52120096 | ||
| A role for the BMP antagonist chordin in endochondral ossification. | Q52124662 | ||
| Direct evidence for an ADP-sensitive phosphointermediate of (K+ + H+)-ATPase. | Q52655697 | ||
| Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells. | Q54030597 | ||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sclerostin | Q7434196 |
| negative regulation of BMP signaling pathway | Q14874551 | ||
| Sclerostin | Q14887297 | ||
| P304 | page(s) | 6267-76 | |
| P577 | publication date | 2003-12-01 | |
| P1433 | published in | The EMBO Journal | Q1278554 |
| P1476 | title | Osteocyte control of bone formation via sclerostin, a novel BMP antagonist | |
| P478 | volume | 22 |
| Q35755034 | A Comprehensive Overview of Skeletal Phenotypes Associated with Alterations in Wnt/β-catenin Signaling in Humans and Mice |
| Q35952286 | A DNA binding mutation in estrogen receptor-α leads to suppression of Wnt signaling via β-catenin destabilization in osteoblasts |
| Q35578826 | A Novel Loss-of-Sclerostin Function Mutation in a First Egyptian Family with Sclerosteosis |
| Q55256056 | A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis. |
| Q38986443 | A Sclerostin super-producer cell line derived from the human cell line SaOS-2: a new tool for the study of the molecular mechanisms driving Sclerostin expression. |
| Q46281147 | A crucial role for matrix metalloproteinase 2 in osteocytic canalicular formation and bone metabolism |
| Q64240766 | A novel nonosteocytic regulatory mechanism of bone modeling |
| Q30502342 | A novel underuse model shows that inactivity but not ovariectomy determines the deteriorated material properties and geometry of cortical bone in the tibia of adult rats. |
| Q34264395 | A review of osteocyte function and the emerging importance of sclerostin |
| Q34442832 | A roadmap to the brittle bones of cystic fibrosis |
| Q82420731 | A sclerostin-based theory for strain-induced bone formation |
| Q92838130 | Accelerated development of instability-induced osteoarthritis in transgenic mice overexpressing SOST |
| Q35586060 | Activation of HIFa pathway in mature osteoblasts disrupts the integrity of the osteocyte/canalicular network |
| Q34126530 | Activation of bone remodeling after fatigue: differential response to linear microcracks and diffuse damage |
| Q35410684 | Acute-phase protein serum amyloid A3 is a novel paracrine coupling factor that controls bone homeostasis |
| Q38725053 | Advanced oxidation protein products induce apoptosis, and upregulate sclerostin and RANKL expression, in osteocytic MLO-Y4 cells via JNK/p38 MAPK activation |
| Q36979410 | Age-dependent Wnt gene expression in bone and during the course of osteoblast differentiation |
| Q38896053 | Agonists and Antagonists of TGF-β Family Ligands |
| Q37601765 | Alterations in gene expression precede sarcopenia and osteopenia in botulinum toxin immobilized mice |
| Q38275068 | Alterations in vitamin D metabolite, parathyroid hormone and fibroblast growth factor-23 concentrations in sclerostin-deficient mice permit the maintenance of a high bone mass. |
| Q35085009 | An Akt-dependent increase in canonical Wnt signaling and a decrease in sclerostin protein levels are involved in strontium ranelate-induced osteogenic effects in human osteoblasts. |
| Q36986316 | An integrated understanding of the physiological response to elevated extracellular phosphate. |
| Q36752277 | Anabolic agents and the bone morphogenetic protein pathway |
| Q35110851 | Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice |
| Q37316092 | Anatomic variations of the lacunar-canalicular system influence solute transport in bone |
| Q36796273 | Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis |
| Q34701183 | Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling |
| Q94333866 | Anti‐sclerostin antibodies for the treatment of osteoporosis |
| Q38570326 | Appropriate models for novel osteoporosis drug discovery and future perspectives |
| Q56985054 | Association between SOST gene polymorphisms and response to alendronate treatment in postmenopausal Chinese women with low bone mineral density |
| Q37222697 | BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway. |
| Q33723850 | BMP-2 modulates beta-catenin signaling through stimulation of Lrp5 expression and inhibition of beta-TrCP expression in osteoblasts |
| Q99406397 | BMP-induced Atoh8 attenuates osteoclastogenesis by suppressing Runx2 transcriptional activity and reducing the Rankl/Opg expression ratio in osteoblasts |
| Q46042524 | BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction |
| Q28566615 | Binge alcohol-induced bone damage is accompanied by differential expression of bone remodeling-related genes in rat vertebral bone |
| Q36013464 | Biomechanical Screening of Cell Therapies for Vocal Fold Scar |
| Q34646678 | Biomechanical forces in the skeleton and their relevance to bone metastasis: biology and engineering considerations. |
| Q28066397 | Bone Cells Dynamics during Peri-Implantitis: a Theoretical Analysis |
| Q99561826 | Bone Marrow Microvasculature |
| Q37947050 | Bone Morphogenetic Protein functions as a context-dependent angiogenic cue in vertebrates |
| Q37801468 | Bone Morphogenetic Proteins: A critical review |
| Q35603116 | Bone anabolic agents for the treatment of multiple myeloma |
| Q38593977 | Bone as a Target Organ in Rheumatic Disease: Impact on Osteoclasts and Osteoblasts |
| Q27010173 | Bone as an endocrine organ |
| Q41834754 | Bone balance within a cortical BMU: local controls of bone resorption and formation. |
| Q90116081 | Bone health in diabetes and prediabetes |
| Q64044632 | Bone metabolism in Langerhans cell histiocytosis |
| Q33835723 | Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis |
| Q37764890 | Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists |
| Q24299076 | Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function |
| Q48003981 | Bone remodeling as a spatial evolutionary game |
| Q26797366 | Bone remodeling in the context of cellular and systemic regulation: the role of osteocytes and the nervous system |
| Q34418714 | Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. |
| Q36407024 | Building bone to reverse osteoporosis and repair fractures |
| Q34463986 | Buried alive: how osteoblasts become osteocytes |
| Q24293652 | CYR61 regulates BMP-2-dependent osteoblast differentiation through the {alpha}v{beta}3 integrin/integrin-linked kinase/ERK pathway |
| Q39446891 | Calcitonin: physiology or fantasy? |
| Q34974487 | Canonical Wnts function as potent regulators of osteogenesis by human mesenchymal stem cells |
| Q37778779 | Cellular communications in bone homeostasis and repair |
| Q36561855 | Changes in bone sclerostin levels in mice after ovariectomy vary independently of changes in serum sclerostin levels |
| Q48762542 | Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study. |
| Q38746257 | Changing concept in treatment of asymptomatic severe aortic stenosis and normal ejection fraction: time for biomarkers reappraisal |
| Q85774979 | Characteristics of alveolar bone associated with physiological movement of molar in mice: a histological and histochemical study |
| Q64118009 | Characterization of a novel murine Sost ER Cre model targeting osteocytes |
| Q54661657 | Characterization of osteocrin expression in human bone. |
| Q36670205 | Characterization of skeletal alterations in a model of prematurely aging mice |
| Q27653715 | Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION |
| Q37371753 | Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals |
| Q40031994 | Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness |
| Q38976490 | Class I and IIa histone deacetylases have opposite effects on sclerostin gene regulation |
| Q38793515 | Comparison of black, green and rooibos tea on osteoblast activity. |
| Q49670897 | Comparison of clinical, biochemical and histomorphometric analysis of bone biopsies in dialysis patients with and without fractures |
| Q51673654 | Comparison of tissue transglutaminase 2 and bone biological markers osteocalcin, osteopontin and sclerostin expression in human osteoporosis and osteoarthritis. |
| Q51518471 | Contribution of the sclerostin domain-containing protein 1 (SOSTDC1) gene to normal variation of peak bone mineral density in Chinese women and men. |
| Q27300741 | Control of bone mass and remodeling by PTH receptor signaling in osteocytes |
| Q24337339 | Control of the SOST bone enhancer by PTH using MEF2 transcription factors |
| Q64141328 | Crosstalk between MLO-Y4 osteocytes and C2C12 muscle cells is mediated by the Wnt/β-catenin pathway |
| Q37526818 | Crosstalk between Wnt and bone morphogenic protein signaling: a turbulent relationship |
| Q54974118 | DNA Methylation in Osteoarthritis: Current Status and Therapeutic Implications. |
| Q42498840 | DNA methylation contributes to the regulation of sclerostin expression in human osteocytes. |
| Q35816932 | DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter |
| Q82280423 | Decreased serum sclerostin levels in patients with primary hyperparathyroidism: a cross-sectional and a longitudinal study |
| Q35101832 | Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays |
| Q33564617 | Developments in sclerostin biology: regulation of gene expression, mechanisms of action, and physiological functions |
| Q34768838 | Differential expression of sclerostin in adult and juvenile mouse calvariae |
| Q37324643 | Differential gene expression in the perichondrium and cartilage of the neonatal mouse temporomandibular joint |
| Q36619465 | Differential sclerostin and parathyroid hormone response to exercise in boys and men. |
| Q24621990 | Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways |
| Q38233800 | Diversity is in my veins: role of bone morphogenetic protein signaling during venous morphogenesis in zebrafish illustrates the heterogeneity within endothelial cells |
| Q39699020 | Does Sclerostin Depletion Stimulate Fracture Healing in a Mouse Model? |
| Q50020853 | Drug development in the era of precision medicine. |
| Q38814167 | E11/Podoplanin Protein Stabilization Through Inhibition of the Proteasome Promotes Osteocyte Differentiation in Murine in Vitro Models |
| Q44103030 | Early postnatal lethality and cardiovascular defects in CXCR7-deficient mice |
| Q41736361 | Effect of mechanical stimuli on skeletal regeneration around implants |
| Q24631082 | Effects of PTH on osteocyte function |
| Q46021670 | Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats. |
| Q36474269 | Effects of growth factors and cytokines on osteoblast differentiation. |
| Q80430359 | Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone |
| Q53669998 | Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing. |
| Q91404818 | Elevated glucose acts directly on osteocytes to increase sclerostin expression in diabetes |
| Q36099415 | Emerging and potential therapies for osteoporosis |
| Q36944034 | Emerging pharmacologic therapies for osteoporosis |
| Q39090721 | Emerging treatment approaches for myeloma-related bone disease |
| Q27008987 | Endocrine crosstalk between muscle and bone |
| Q33737865 | Enhanced prostacyclin formation and Wnt signaling in sclerostin deficient osteocytes and bone. |
| Q51124369 | Estrogen alone or in combination with parathyroid hormone can decrease vertebral MEF2 and sclerostin expression and increase vertebral bone mass in ovariectomized rats. |
| Q45987051 | Evaluation of the effects of systemic treatment with a sclerostin neutralizing antibody on bone repair in a rat femoral defect model. |
| Q47641256 | Ex vivo construction of human primary 3D-networked osteocytes |
| Q39255803 | Exploiting the WNT Signaling Pathway for Clinical Purposes |
| Q61801789 | Expression of Sclerostin in Osteoporotic Fracture Patients Is Associated with DNA Methylation in the CpG Island of the Gene |
| Q38696859 | Expression of Wnt signaling skeletal development genes in the cartilaginous fish, elephant shark (Callorhinchus milii). |
| Q36213693 | Expression of sclerostin in the developing zebrafish (Danio rerio) brain and skeleton |
| Q43636568 | FGF18 represses noggin expression and is induced by calcineurin |
| Q92313879 | FOXO1 Mediates Advanced Glycation End Products Induced Mouse Osteocyte-Like MLO-Y4 Cell Apoptosis and Dysfunctions |
| Q38365059 | Fate of growth plate hypertrophic chondrocytes: death or lineage extension? |
| Q27693233 | Fluorescence-based force/tension sensors: a novel tool to visualize mechanical forces in structural proteins in live cells |
| Q92621353 | Focal adhesion protein Kindlin-2 regulates bone homeostasis in mice |
| Q26764854 | From disease to treatment: from rare skeletal disorders to treatments for osteoporosis |
| Q28385120 | From estrogen-centric to aging and oxidative stress: a revised perspective of the pathogenesis of osteoporosis |
| Q88769649 | From skeletal development to the creation of pluripotent stem cell-derived bone-forming progenitors |
| Q38367220 | From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD. |
| Q36532502 | Function of BMPs and BMP antagonists in adult bone |
| Q27002647 | Functions of the osteocyte network in the regulation of bone mass |
| Q37777644 | Genetic epidemiology of age-related osteoporosis and its clinical applications. |
| Q28509512 | Genetic evidence that SOST inhibits WNT signaling in the limb |
| Q57558980 | Genetic variation in Wnt/β-catenin and ER signalling pathways in female and male elite dancers and its associations with low bone mineral density: a cross-section and longitudinal study |
| Q37681343 | Genetics of osteoporosis: accelerating pace in gene identification and validation |
| Q33891844 | Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease |
| Q60928210 | Gingival crevicular fluid levels of sclerostin in chronic periodontitis and healthy subjects |
| Q37482220 | Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice |
| Q37714895 | Glucocorticoid suppression of osteocyte perilacunar remodeling is associated with subchondral bone degeneration in osteonecrosis |
| Q37003240 | Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization |
| Q35187105 | Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. |
| Q34776085 | HIF-1α inhibits Wnt signaling pathway by activating Sost expression in osteoblasts |
| Q36104814 | High Parathyroid Hormone Level and Osteoporosis Predict Progression of Coronary Artery Calcification in Patients on Dialysis |
| Q39342144 | Higher serum sclerostin levels and insufficiency of vitamin D are strongly associated with vertebral fractures in hemodialysis patients: a case control study. |
| Q50051081 | Histochemical examination on the peri-implant bone with early occlusal loading after the immediate placement into extraction sockets |
| Q37402642 | How genomics has informed our understanding of the pathogenesis of osteoporosis |
| Q92066450 | How much do we know about the role of osteocytes in different phases of fracture healing? A systematic review |
| Q64250211 | Hydrofluoric acid treatment of titanium surfaces enhances the proliferation of human gingival fibroblasts |
| Q33895465 | Hypoxia decreases sclerostin expression and increases Wnt signaling in osteoblasts |
| Q34614690 | Identification and characterization of microRNAs controlled by the osteoblast-specific transcription factor Osterix |
| Q38338282 | Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling |
| Q46287351 | Identification of novel regulators of osteoblast matrix mineralization by time series transcriptional profiling |
| Q36453030 | Identification of osteocyte‐selective proteins |
| Q98778455 | Identification of osteogenic progenitor cell-targeted peptides that augment bone formation |
| Q42812150 | Immunolocalization of DMP1 and sclerostin in the epiphyseal trabecule and diaphyseal cortical bone of osteoprotegerin deficient mice |
| Q36445723 | Impact of Gap Junctional Intercellular Communication on MLO-Y4 Sclerostin and Soluble Factor Expression |
| Q26829246 | Impact of inflammation on the osteoblast in rheumatic diseases |
| Q41652905 | In vitro osteocytic microdamage and viability quantification using a microloading platform |
| Q30990351 | Increase in Dickkopf-1 Serum Level in Recent Spondyloarthritis. Data from the DESIR Cohort |
| Q31038073 | Increased Dickkopf-1 in Recent-onset Rheumatoid Arthritis is a New Biomarker of Structural Severity. Data from the ESPOIR Cohort |
| Q44774590 | Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. |
| Q35260816 | Increased sclerostin levels after further ablation of remnant estrogen by aromatase inhibitors. |
| Q37989394 | Inflammatory bone loss: pathogenesis and therapeutic intervention |
| Q38861665 | Inhibition of GSK3β Stimulates BMP Signaling and Decreases SOST Expression Which Results in Enhanced Osteoblast Differentiation. |
| Q42966206 | Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats |
| Q37994636 | Intercellular cross-talk among bone cells: new factors and pathways. |
| Q47858273 | Interleukin-12 modulates the immunomodulatory properties of human periodontal ligament cells |
| Q36786605 | Isolation and Functional Analysis of an Immortalized Murine Cementocyte Cell Line, IDG-CM6 |
| Q36730826 | Isolation and culture of primary osteocytes from the long bones of skeletally mature and aged mice |
| Q35570431 | Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases |
| Q36917546 | Lactating Ctcgrp nulls lose twice the normal bone mineral content due to fewer osteoblasts and more osteoclasts, whereas bone mass is fully restored after weaning in association with up-regulation of Wnt signaling and other novel genes |
| Q37325079 | Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo |
| Q36117524 | Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression |
| Q38186661 | Local strategies to prevent and treat osteoporosis |
| Q48853983 | Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women |
| Q39374128 | Low-Density Lipoprotein Receptor-Related Proteins in Skeletal Development and Disease |
| Q44833234 | Lower fracture risk in older men with higher sclerostin concentration: a prospective analysis from the MINOS study. |
| Q30914003 | Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo |
| Q55360643 | Lrp4: A novel modulator of extracellular signaling in craniofacial organogenesis. |
| Q47428797 | MANAGEMENT OF ENDOCRINE DISEASE: Novel anabolic treatments for osteoporosis |
| Q58557105 | MPBPK-TMDD models for mAbs: alternative models, comparison, and identifiability issues |
| Q38529341 | Matrix mineralization as a trigger for osteocyte maturation |
| Q35831180 | Mechanical loading-related changes in osteocyte sclerostin expression in mice are more closely associated with the subsequent osteogenic response than the peak strains engendered |
| Q90450301 | Mechanical regulation of bone homeostasis through p130Cas-mediated alleviation of NF-κB activity |
| Q40426618 | Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases, and ERKs |
| Q35645894 | Mechanism by which MLO-A5 late osteoblasts/early osteocytes mineralize in culture: similarities with mineralization of lamellar bone |
| Q33864136 | Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways |
| Q27022580 | Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis |
| Q36548328 | Modulator of bone morphogenetic protein activity in the progression of kidney diseases |
| Q98465934 | Molecular mechanisms and clinical management of cancer bone metastasis |
| Q35902283 | Molecular recognition in bone morphogenetic protein (BMP)/receptor interaction |
| Q92349783 | Molecular-Based Treatment Strategies for Osteoporosis: A Literature Review |
| Q34339627 | Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation |
| Q38971111 | Murine embryonic fibroblast cell lines differentiate into three mesenchymal lineages to different extents: new models to investigate differentiation processes |
| Q28535490 | Mutational analysis of sclerostin shows importance of the flexible loop and the cystine-knot for Wnt-signaling inhibition |
| Q57794000 | Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies |
| Q38246241 | Myeloma bone disease: pathogenesis, current treatments and future targets |
| Q36595304 | Myelopoiesis is regulated by osteocytes through Gsα-dependent signaling |
| Q33570529 | Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. |
| Q39151180 | New Target Sites for Treatment of Osteoporosis |
| Q28267086 | Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex |
| Q40314448 | Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro |
| Q38470745 | Novel targets for the prevention of osteoporosis - lessons learned from studies of metabolic bone disorders |
| Q34025065 | Novel therapeutic targets in myeloma bone disease |
| Q33558145 | Nuclear alpha NAC influences bone matrix mineralization and osteoblast maturation in vivo |
| Q80406498 | OPG and RANKL mRNA and protein expressions in the primary and secondary metaphyseal trabecular bone of PTH-treated rats are independent of that of SOST |
| Q42092681 | Opposite spectrum of activity of canonical Wnt signaling in the osteogenic context of undifferentiated and differentiated mesenchymal cells: implications for tissue engineering |
| Q34637681 | OstemiR: a novel panel of microRNA biomarkers in osteoblastic and osteocytic differentiation from mesencymal stem cells |
| Q35059741 | Osteo-renal regulation of systemic phosphate metabolism |
| Q39190775 | Osteoblast-osteoclast interactions |
| Q33877602 | Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis |
| Q38230277 | Osteocyte control of bone remodeling: is sclerostin a key molecular coordinator of the balanced bone resorption-formation cycles? |
| Q42814254 | Osteocyte differentiation is regulated by extracellular matrix stiffness and intercellular separation |
| Q34328711 | Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading |
| Q49847220 | Osteocyte regulation of bone and blood |
| Q37981072 | Osteocyte regulation of bone mineral: a little give and take. |
| Q35032099 | Osteocyte-derived insulin-like growth factor I is not essential for the bone repletion response in mice |
| Q37626024 | Osteocyte-driven bone remodeling |
| Q37702918 | Osteocyte: the unrecognized side of bone tissue |
| Q36357606 | Osteocytes and Skeletal Pathophysiology |
| Q37702067 | Osteocytes and WNT: the mechanical control of bone formation. |
| Q37958204 | Osteocytes: central conductors of bone biology in normal and pathological conditions |
| Q55517542 | Osteocytic oxygen sensing controls bone mass through epigenetic regulation of sclerostin. |
| Q42813557 | Osteogenesis induced by frizzled-related protein (FRZB) is linked to the netrin-like domain |
| Q46288096 | Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease |
| Q47677127 | Osteogenic Potential of Caspases Related to Endochondral Ossification. |
| Q37297529 | PTH and PTHrP signaling in osteoblasts |
| Q35229920 | PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. |
| Q55082811 | Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. |
| Q35156214 | Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice |
| Q36177028 | Parathyroid hormone induces differentiation of mesenchymal stromal/stem cells by enhancing bone morphogenetic protein signaling |
| Q28567926 | Parathyroid hormone signaling through low-density lipoprotein-related protein 6 |
| Q47734632 | Pathogenesis of bone disease in multiple myeloma: from bench to bedside |
| Q84981661 | Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls |
| Q38645229 | Periodontal Ligament and Alveolar Bone in Health and Adaptation: Tooth Movement |
| Q35234328 | Physiology of Mechanotransduction: How Do Muscle and Bone "Talk" to One Another? |
| Q90751368 | Pigment epithelium derived factor regulates human Sost/Sclerostin and other osteocyte gene expression via the receptor and induction of Erk/GSK-3beta/beta-catenin signaling |
| Q24534143 | Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites |
| Q42020582 | Production and characterization of monoclonal antibodies to human sclerostin |
| Q33596475 | Profile of romosozumab and its potential in the management of osteoporosis |
| Q21560844 | Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression |
| Q46203128 | Protein related to DAN and cerberus (PRDC) inhibits osteoblastic differentiation and its suppression promotes osteogenesis in vitro |
| Q51741993 | Pulsed electromagnetic fields preserve bone architecture and mechanical properties and stimulate porous implant osseointegration by promoting bone anabolism in type 1 diabetic rabbits. |
| Q52915154 | Rapamycin reduces severity of senile osteoporosis by activating osteocyte autophagy. |
| Q37248630 | Recent advances in the noninvasive diagnosis of renal osteodystrophy |
| Q47183965 | Recombinant sclerostin antagonises effects of ex vivo mechanical loading in trabecular bone and increases osteocyte lacunar size |
| Q34260123 | Reduced renal calcium excretion in the absence of sclerostin expression: evidence for a novel calcium-regulating bone kidney axis. |
| Q64076615 | Regulation of Proliferation, Differentiation and Functions of Osteoblasts by Runx2 |
| Q57265500 | Regulation of Sclerostin Expression by Paracrine and Endocrine Factors |
| Q40111192 | Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease |
| Q28286814 | Regulation of Wnt/β-catenin signaling within and from osteocytes |
| Q37015968 | Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. |
| Q92988138 | Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans |
| Q37109247 | Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis |
| Q90747662 | Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients |
| Q35013412 | Relationship between sclerostin and cardiovascular calcification in hemodialysis patients: a cross-sectional study |
| Q37627846 | Relative influence of heritability, environment and genetics on serum sclerostin |
| Q35673905 | Relevance of Wnt signaling for osteoanabolic therapy |
| Q37226223 | Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes |
| Q47894997 | Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity |
| Q54300423 | Rheumatoid arthritis bone fragility is associated with upregulation of IL17 and DKK1 gene expression. |
| Q33647689 | RhoA GTPase interacts with beta-catenin signaling in clinorotated osteoblasts |
| Q38807230 | Role and mechanism of action of sclerostin in bone |
| Q37673466 | Role of Osteocyte-derived Insulin-Like Growth Factor I in Developmental Growth, Modeling, Remodeling, and Regeneration of the Bone. |
| Q87741639 | Role of Sost in Wnt signal pathway in osteoporosis rats and regulating effect of soybean isoflavones on Wnt signal pathway |
| Q36020434 | Role of fibroblast growth factor 2 and Wnt signaling in anabolic effects of parathyroid hormone on bone formation |
| Q55026099 | Role of the Wnt/β-Catenin Pathway in Renal Osteodystrophy. |
| Q26768186 | Roles of the kidney in the formation, remodeling and repair of bone |
| Q34181023 | SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease |
| Q51998296 | SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. |
| Q24303393 | SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor |
| Q47263016 | SOST, an LNGFR target, inhibits the osteogenic differentiation of rat ectomesenchymal stem cells. |
| Q38986059 | SaOS2 Osteosarcoma cells as an in vitro model for studying the transition of human osteoblasts to osteocytes. |
| Q26744599 | Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges |
| Q36192571 | Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats. |
| Q60949427 | Sclerostin Modulation Holds Promise for Dental Indications |
| Q36762750 | Sclerostin alters serum vitamin D metabolite and fibroblast growth factor 23 concentrations and the urinary excretion of calcium |
| Q34751932 | Sclerostin and Dickkopf-1 in renal osteodystrophy |
| Q36241657 | Sclerostin antibody increases bone volume and enhances implant fixation in a rat model |
| Q36889104 | Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. |
| Q42566430 | Sclerostin binds and regulates the activity of cysteine-rich protein 61. |
| Q40815830 | Sclerostin distribution in children and adolescents with type 1 diabetes mellitus and correlation with bone metabolism and bone mineral density. |
| Q51303428 | Sclerostin expression and functions beyond the osteocyte. |
| Q48233828 | Sclerostin expression in bone tumours and tumour-like lesions. |
| Q41468263 | Sclerostin expression in the subchondral bone of patients with knee osteoarthritis |
| Q57848944 | Sclerostin in Mineralized Matrices and van Buchem Disease |
| Q47327411 | Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. |
| Q28293474 | Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins |
| Q39105382 | Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss |
| Q37661410 | Sclerostin inhibition reverses skeletal fragility in an Lrp5-deficient mouse model of OPPG syndrome |
| Q35694436 | Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis |
| Q100958533 | Sclerostin inhibits Wnt signaling through tandem interaction with two LRP6 ectodomains |
| Q36256294 | Sclerostin inhibits osteoblast differentiation without affecting BMP2/SMAD1/5 or Wnt3a/β-catenin signaling but through activation of platelet-derived growth factor receptor signaling in vitro |
| Q39659778 | Sclerostin is a direct target of osteoblast-specific transcription factor osterix |
| Q35983181 | Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism |
| Q45393385 | Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury |
| Q37492408 | Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. |
| Q38030984 | Sclerostin monoclonal antibodies on bone metabolism and fracture healing |
| Q64928492 | Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. |
| Q31032805 | Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway |
| Q37684437 | Sclerostin's role in bone's adaptive response to mechanical loading |
| Q90406658 | Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review |
| Q90708226 | Sclerostin: a new biomarker of CKD-MBD |
| Q38023902 | Sclerostin: a possible target for the management of cancer-induced bone disease |
| Q47909734 | Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease. |
| Q33992612 | Sclerostin: current knowledge and future perspectives |
| Q37974871 | Sclerostin: therapeutic horizons based upon its actions |
| Q33720166 | Sclerostin–erbB-3 interactions: Modulation of erbB-3 activity by sclerostin |
| Q58565668 | Screening of key candidate genes and pathways for osteocytes involved in the differential response to different types of mechanical stimulation using a bioinformatics analysis |
| Q36626700 | Secreted and transmembrane wnt inhibitors and activators |
| Q50088169 | Serum Sclerostin Levels in Adults With Osteogenesis Imperfecta: Comparison With Normal Individuals and Response to Teriparatide Therapy |
| Q36069858 | Serum sclerostin and risk of hip fracture in older Caucasian women |
| Q34537434 | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis |
| Q36201481 | Serum sclerostin increases in healthy adult men during bed rest. |
| Q33786865 | Serum sclerostin levels negatively correlate with parathyroid hormone levels and free estrogen index in postmenopausal women |
| Q51838030 | Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women. |
| Q36845086 | Serum β -Catenin Levels Associated with the Ratio of RANKL/OPG in Patients with Postmenopausal Osteoporosis |
| Q38730488 | Shedding quantitative fluorescence light on novel regulatory mechanisms in skeletal biomedicine and biodentistry |
| Q89920340 | Should We Consider the Cardiovascular System While Evaluating CKD-MBD? |
| Q38974110 | Signalling pathways in trophic skeletal development and morphogenesis: Insights from studies on teleost fish |
| Q28286616 | Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody |
| Q30278695 | Single-pulsed electromagnetic field therapy increases osteogenic differentiation through Wnt signaling pathway and sclerostin downregulation |
| Q35041301 | Smad1 plays an essential role in bone development and postnatal bone formation |
| Q37113932 | Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo |
| Q47559021 | Solute Transport in the Bone Lacunar-Canalicular System (LCS). |
| Q37387761 | Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner. |
| Q35635751 | Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading. |
| Q35955921 | Spatial and temporal localization of WNT signaling proteins in a mouse model of distraction osteogenesis |
| Q49789426 | Spina bifida-predisposing heterozygous mutations in Planar Cell Polarity genes and Zic2 reduce bone mass in young mice. |
| Q47896472 | Strongly enhanced levels of sclerostin during human fracture healing. |
| Q46276637 | Strontium ranelate treatment of human primary osteoblasts promotes an osteocyte-like phenotype while eliciting an osteoprotegerin response |
| Q38957057 | Structural Biology and Evolution of the TGF-β Family |
| Q36929011 | Suppression of autophagy in osteocytes mimics skeletal aging |
| Q41432679 | Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels. |
| Q39155183 | TGF-β Family Signaling in Connective Tissue and Skeletal Diseases |
| Q35754103 | TGF-β regulates sclerostin expression via the ECR5 enhancer |
| Q35569802 | TIEG1-NULL OSTEOCYTES DISPLAY DEFECTS IN THEIR MORPHOLOGY, DENSITY AND SURROUNDING BONE MATRIX. |
| Q38108518 | Talking among ourselves: paracrine control of bone formation within the osteoblast lineage |
| Q37199498 | Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses |
| Q36212807 | Targeted deletion of Sost distal enhancer increases bone formation and bone mass |
| Q35603128 | Targeting bone as a therapy for myeloma. |
| Q41498366 | The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5. |
| Q92712185 | The Autophagy in Osteoimmonology: Self-Eating, Maintenance, and Beyond |
| Q36242266 | The BMP signaling and in vivo bone formation |
| Q53692068 | The BMP-2 mutant L51P: a BMP receptor IA binding-deficient inhibitor of noggin. |
| Q57168746 | The Biological Enhancement of Spinal Fusion for Spinal Degenerative Disease |
| Q27025762 | The DAN family: modulators of TGF-β signaling and beyond |
| Q52653928 | The Deletion of Hdac4 in Mouse Osteoblasts Influences Both Catabolic and Anabolic Effects in Bone. |
| Q90040615 | The Effects of Tocotrienol on Bone Peptides in a Rat Model of Osteoporosis Induced by Metabolic Syndrome: The Possible Communication between Bone Cells |
| Q33627749 | The Impact of Glucagon-Like Peptide-1 on Bone Metabolism and Its Possible Mechanisms. |
| Q38687054 | The Lrp4R1170Q Homozygous Knock-In Mouse Recapitulates the Bone Phenotype of Sclerosteosis in Humans |
| Q64268866 | The Role of Osteocytes in Inflammatory Bone Loss |
| Q39107516 | The Role of the Osteocyte in Bone and Nonbone Disease |
| Q38183365 | The Roles of Fibroblast Growth Factor (FGF)-23, α-Klotho and Furin Protease in Calcium and Phosphate Homeostasis : A Mini-Review |
| Q38407357 | The WNT system: background and its role in bone |
| Q40379709 | The association between sclerostin and incident type 2 diabetes risk: a cohort study. |
| Q39101623 | The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology |
| Q38545213 | The dynamic skeleton |
| Q33278730 | The effect of low-level laser therapy during orthodontic movement: a preliminary study |
| Q37291429 | The effect on proliferation and differentiation of cementoblast by using sclerostin as inhibitor |
| Q27009129 | The osteocyte as a therapeutic target in the treatment of osteoporosis |
| Q37203605 | The osteocyte: an endocrine cell ... and more |
| Q33565236 | The role of DNA methylation in common skeletal disorders |
| Q63230117 | The role of sclerostin and dickkopf-1 in oral tissues – A review from the perspective of the dental disciplines |
| Q40432910 | The sclerostin-bone protein interactome |
| Q34428195 | The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors |
| Q38012387 | Toward mechanical systems biology in bone |
| Q35560337 | Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats |
| Q35854185 | Treatment of a mouse model of ankylosing spondylitis with exogenous sclerostin has no effect on disease progression. |
| Q49375971 | Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors |
| Q36083303 | Update on Wnt signaling in bone cell biology and bone disease. |
| Q64230394 | Update on the impact of type 2 diabetes mellitus on bone metabolism and material properties |
| Q37893542 | Use and efficacy of bone morphogenetic proteins in fracture healing. |
| Q36793394 | Validation of commercially available ELISAs for the detection of circulating sclerostin in hemodialysis patients |
| Q43879015 | Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers |
| Q35468562 | Vitamin D and hyperparathyroidism in obesity |
| Q51490626 | Voluntary exercise has long-term in vivo protective effects on osteocyte viability and bone strength following ovariectomy. |
| Q93197739 | WNT Signaling and Bone: Lessons From Skeletal Dysplasias and Disorders |
| Q28285090 | WNT signaling in bone homeostasis and disease: from human mutations to treatments |
| Q100316356 | WNT-β-catenin signalling - a versatile player in kidney injury and repair |
| Q33553692 | Wise regulates bone deposition through genetic interactions with Lrp5 |
| Q92136364 | Wnt Antagonists in Hematopoietic and Immune Cell Fate: Implications for Osteoporosis Therapies |
| Q37724188 | Wnt and the Wnt signaling pathway in bone development and disease |
| Q37943458 | Wnt proteins in mineralized tissue development and homeostasis |
| Q36700498 | Wnt signaling and skeletal development |
| Q83588890 | Wnt signaling as a therapeutic target for bone diseases |
| Q36418026 | Wnt signaling in bone development and disease: making stronger bone with Wnts |
| Q36638647 | Wnt signaling in bone formation and its therapeutic potential for bone diseases |
| Q37427485 | Wnt signaling in bone metabolism |
| Q38128460 | Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches |
| Q36268339 | Wnt signalling pathway: a new target for the treatment of osteoporosis |
| Q33673894 | Wnt-β-catenin signaling pathway inhibition by sclerostin may protect against degradation in healthy but not osteoarthritic cartilage |
| Q38807957 | Wnt/β-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance. |
| Q34709060 | Wnts produced by Osterix-expressing osteolineage cells regulate their proliferation and differentiation. |
| Q98466734 | lncRNA MEG3 Suppresses the Progression of Ankylosis Spondylitis by Regulating the Let-7i/SOST Axis |
| Q41811415 | rBMP represses Wnt signaling and influences skeletal progenitor cell fate specification during bone repair. |
Search more.